title: Severity of Staphylococcus aureus infection of the skin is associated with inducibility of human beta-defensin 3 but not human beta-defensin 2.
abstract: Gram-positive bacteria are the predominant cause of skin infections. Antimicrobial peptides (AMPs) are believed to be of major importance in skin's innate defense against these pathogens. This study aimed at providing clinical evidence for the contribution of AMP inducibility to determining the severity of Gram-positive skin infection. Using real-time PCR, we determined the induction of human beta-defensin 2 (HBD-2), HBD-3, and RNase 7 by comparing healthy and lesional mRNA levels in 32 patients with Gram-positive skin infection. We then examined whether AMP induction differed by disease severity, as measured by number of recurrences and need for surgical drainage in patients with Staphylococcus aureus-positive lesions. We found that HBD-2 and -3, but not RNase 7, mRNA expression was highly induced by Gram-positive bacterial infection in otherwise healthy skin. Less induction of HBD-3, but not HBD-2, was associated with more-severe S. aureus skin infection: HBD-3 mRNA levels were 11.4 times lower in patients with more than 6 recurrences (P = 0.01) and 8.8 times lower in patients reporting surgical drainage (P = 0.01) than in the respective baseline groups. This suggests that inducibility of HBD-3 influences the severity of Gram-positive skin infection in vivo. The physiological function of HBD-2 induction in this context remains unclear.
authors.affiliation: Institut für Tropenmedizin, Eberhard Karls Universität, Tübingen, Germany. philipp.zanger@med.uni-tuebingen.de
authors.forename: Philipp
authors.initials: P
authors.lastname: Zanger
authors.forename: Johannes
authors.initials: J
authors.lastname: Holzer
authors.forename: Regina
authors.initials: R
authors.lastname: Schleucher
authors.forename: Helmut
authors.initials: H
authors.lastname: Scherbaum
authors.forename: Birgit
authors.initials: B
authors.lastname: Schittek
authors.forename: Sabine
authors.initials: S
authors.lastname: Gabrysch
mesh_terms: D000328:Adult; D005260:Female; D005786:Gene Expression Regulation / Q000276:immunology / Q000502:physiology; D006801:Humans; D008297:Male; D012867:Skin / Q000737:chemistry / Q000276:immunology / Q000382:microbiology; D013207:Staphylococcal Skin Infections / Q000276:immunology*; D013211:Staphylococcus aureus / Q000276:immunology / Q000472:pathogenicity; D015854:Up-Regulation / Q000276:immunology / Q000502:physiology; D055815:Young Adult; D023083:beta-Defensins / Q000032:analysis / Q000096:biosynthesis / Q000502:physiology*
chemical_list: C422950:DEFB103A protein, human; C106641:DEFB4A protein, human; D023083:beta-Defensins
references.citation: Curr Opin Infect Dis. 2008 Apr;21(2):122-8
references.pmid: 18317033
references.citation: J Allergy Clin Immunol. 2008 Jul;122(1):62-8
references.pmid: 18538383
references.citation: Nature. 1997 Jun 26;387(6636):861
references.pmid: 9202117
references.citation: Br J Dermatol. 2009 Jul;161(1):78-89
references.pmid: 19416233
references.citation: J Biol Chem. 2002 Nov 29;277(48):46779-84
references.pmid: 12244054
references.citation: Infect Immun. 2005 Aug;73(8):5241-4
references.pmid: 16041048
references.citation: J Invest Dermatol. 2001 Jul;117(1):106-11
references.pmid: 11442756
references.citation: Nucleic Acids Res. 2001 May 1;29(9):e45
references.pmid: 11328886
references.citation: J Infect Dis. 2009 Dec 15;200(12):1907-15
references.pmid: 19919305
references.citation: Infect Immun. 2006 Dec;74(12):6847-54
references.pmid: 16954397
references.citation: J Biol Chem. 2001 Feb 23;276(8):5707-13
references.pmid: 11085990
references.citation: J Invest Dermatol. 2007 Oct;127(10):2368-80
references.pmid: 17460726
references.citation: Intern Med J. 2005 Dec;35 Suppl 2:S97-105
references.pmid: 16271065
references.citation: J Invest Dermatol. 2007 Mar;127(3):594-604
references.pmid: 17068477
references.citation: Clin Immunol. 2006 Dec;121(3):332-8
references.pmid: 17015038
references.citation: Eur J Dermatol. 2008 Jan-Feb;18(1):11-21
references.pmid: 18086583
references.citation: Br J Dermatol. 2008 Jul;159(1):97-104
references.pmid: 18476959
references.citation: Cell Mol Life Sci. 2006 Feb;63(4):469-86
references.pmid: 16416029
references.citation: Int J Biochem Cell Biol. 1999 Jun;31(6):645-51
references.pmid: 10404637
references.citation: Infect Immun. 2003 Jul;71(7):3730-9
references.pmid: 12819054
references.citation: Clin Diagn Lab Immunol. 2003 Jan;10(1):161-6
references.pmid: 12522054
references.citation: J Travel Med. 2008 Mar-Apr;15(2):137-9
references.pmid: 18346251
references.citation: Br J Dermatol. 2003 Jan;148(1):188-91
references.pmid: 12534631
references.citation: J Immunol. 2005 Apr 15;174(8):4870-9
references.pmid: 15814714
references.citation: N Engl J Med. 2002 Oct 10;347(15):1151-60
references.pmid: 12374875
references.citation: J Infect Dis. 2007 Nov 1;196(9):1425-30
references.pmid: 17922409
references.citation: J Invest Dermatol. 2001 Nov;117(5):1120-5
references.pmid: 11710922